&lt;h3&gt;&amp;nbsp;&lt;/h3&gt;
&lt;h3&gt;ဘစ်တာဗီ ( ဘစ်တီဂရာဗာ/ အမ်ထရီစီတဘင်း/ တီနိုဖိုဗာ အလာဖီနမိုက် ) သည် HIV ကုသရေး ဆေးဝါးဖြစ်ပြီး အွန်လိုင်းမှ ယခုပင် ဝယ်ယူနိုင်ပါပီ။&lt;/h3&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style=&quot;-qt-block-indent: 0; text-indent: 0px; margin: 0px;&quot;&gt;&lt;strong&gt;အကယ်၍ သင်သည် စစ်မှန်သော၊မူရင်း ( သို့မဟုတ် ) ယေဘုယျဘစ်တာဗီကို ရှာဖွေနေပါက&amp;nbsp;&lt;a href=&quot;mailto:info.silom@pulse-clinic.com&quot;&gt;info.bkk@pulse-clinic.com&lt;/a&gt;&amp;nbsp;သို့ အီးမေးလ်ပို့ပါ ( သို့မဟုတ် ) သင်နှစ်သက်သော ပလပ်ဖောင်းပေါ်တွင် ကျွန်ုပ်တို့နှင့် စကားပြောပါ။&lt;/strong&gt;&lt;/p&gt;
&lt;p style=&quot;-qt-block-indent: 0; text-indent: 0px; margin: 0px;&quot;&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style=&quot;-qt-block-indent: 0; text-indent: 0px; margin: 0px;&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;a href=&quot;https://wa.me/66842262569&quot;&gt;&lt;img src=&quot;https://cms.pulse-clinic.com/Files/WhatsApp.png&quot; width=&quot;48&quot; height=&quot;82&quot; /&gt; &lt;span class=&quot;w-30 inline-block px-2 md:px-4 mt-3&quot;&gt; +66-84-226-2569&amp;nbsp;&lt;/span&gt;&lt;/a&gt;&lt;a href=&quot;https://line.me/ti/p/~@442yeswp&quot;&gt;&lt;img src=&quot;https://cms.pulse-clinic.com/Files/line-logo.png&quot; width=&quot;50&quot; height=&quot;85&quot; /&gt; &lt;span class=&quot;w-30 inline-block px-2 mt-3&quot;&gt; @442yeswp&amp;nbsp;&lt;/span&gt;&lt;/a&gt;&lt;a href=&quot;weixin://dl/chat?pulseclinic&quot;&gt; &lt;img src=&quot;https://cms.pulse-clinic.com/Files/WeChat_App_Icon.png&quot; width=&quot;50&quot; height=&quot;85&quot; /&gt; &lt;span class=&quot;w-30 inline-block px-2 mt-3&quot;&gt; PulseClinic&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;a href=&quot;https://www.pulse-living.com/product/MTA4MTs=&quot;&gt;&lt;img src=&quot;https://cms.pulse-clinic.com/Files/HIV%20MEDS/Hiv-drugs-Biktarvy-buy-Biktarvy-online-hiv-treatment-pulse-clinic-2.jpg&quot; width=&quot;1200&quot; height=&quot;800&quot; style=&quot;display: block; margin-left: auto; margin-right: auto;&quot; /&gt;&lt;/a&gt;&lt;/p&gt;
&lt;p style=&quot;-qt-block-indent: 0; text-indent: 0px; margin: 0px;&quot;&gt;ကိုးကားချက်များ:&amp;nbsp;&lt;/p&gt;
&lt;div class=&quot;field-item&quot;&gt;
&lt;p&gt;Wohl D et al.&amp;nbsp;&lt;em&gt;A phase 3, randomized, controlled clinical trial of bictegravir in a fixed-dose combination, B/F/TAF, vs ABC/DTG/3TC in treatment-na&amp;iuml;ve adults at week 96&lt;/em&gt;. IDWeek, abstract LB4, 2018.&lt;br /&gt;&lt;a href=&quot;https://idsa.confex.com/idsa/2018/webprogram/Paper74246.html&quot;&gt;https://idsa.confex.com/idsa/2018/webprogram/Paper74246.html&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;Orkin C et al (Squires K presenting).&amp;nbsp;&lt;em&gt;Doravirine/lamivudine/tenofovir DF continues to be non-inferior to efavirenz/emtricitabine/tenofovir DF in treatment-naive adults with HIV-1 infection: week 96 results of the DRIVE-AHEAD trial&lt;/em&gt;&lt;em&gt;.&amp;nbsp;&lt;/em&gt;IDWeek, abstract LB1, 2018.&lt;br /&gt;&lt;a href=&quot;https://idsa.confex.com/idsa/2018/webprogram/Paper73851.html&quot;&gt;https://idsa.confex.com/idsa/2018/webprogram/Paper73851.html&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;&lt;em&gt;Update: Following the conference presentation, this study was published in a peer-reviewed journal:&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;Orkin C et al.&lt;em&gt;&lt;a href=&quot;https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa822/6041522&quot;&gt;&amp;nbsp;Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial&lt;/a&gt;&lt;/em&gt;. Clinical Infectious Diseases, ciaa822, December 2020 (open access).&lt;br /&gt;&lt;a href=&quot;https://doi.org/10.1093/cid/ciaa822&quot;&gt;https://doi.org/10.1093/cid/ciaa822&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;Eron J et al.&amp;nbsp;&lt;em&gt;Efficacy and safety of switching from boosted-protease inhibitors (bPI) plus emtricitabine/tenofovir disoproxil fumarate (F/TDF) regimens to the once daily (QD), single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically-suppressed, hiv-1-infected adults: week 96 results of the phase 3, randomized, non-inferiority EMERALD trial.&amp;nbsp;&lt;/em&gt;IDWeek, abstract 1768, 2018.&lt;br /&gt;&lt;a href=&quot;https://idsa.confex.com/idsa/2018/webprogram/Paper72755.html&quot;&gt;https://idsa.confex.com/idsa/2018/webprogram/Paper72755.html&lt;/a&gt;&lt;/p&gt;
&lt;/div&gt;